Form 4: Kiniksa Pharmaceuticals CFO Awarded Performance Share Units and Options Tied to KPL-387 Development

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, received performance-based share units and options linked to the progress of KPL-387, a treatment for recurrent pericarditis.

Summary

• Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, was granted performance share units (PSUs) and performance share options on May 1, 2025.
• The PSUs and options are contingent upon the achievement of specific performance criteria related to KPL-387, a treatment for recurrent pericarditis.
• A total of 4,558 PSUs will vest upon submission of a biologics license application (BLA) to the FDA for KPL-387, while 4,786 PSUs will vest upon FDA approval for commercial sale and marketing of KPL-387.
• Additionally, 7,368 performance share options will vest upon BLA submission, and 7,606 options will vest upon FDA approval.
• The earnout percentage for the PSUs can range from 0% to 100%, depending on the timing of performance criteria achievement.
• The performance share options have an exercise price of $27.74 and expire on April 30, 2035.
• Vesting of both PSUs and options is subject to the participant's continued employment with the company, with certain exceptions.

Sentiment

Score: 7

Explanation: The document is neutral to positive. It describes standard executive compensation practices tied to key development milestones. The sentiment is driven by the potential for future value creation if KPL-387 is successfully developed and commercialized.

Positives

• The structure of the awards aligns management's interests with the successful development and commercialization of KPL-387.
• The vesting criteria are tied to tangible milestones (FDA submission and approval), providing clear targets for performance.
• The long-term expiration date of the options (April 30, 2035) incentivizes sustained effort and commitment.

Risks

• The vesting of the PSUs and options is contingent upon FDA submission and approval, which are subject to regulatory risks and uncertainties.
• Continued employment is a requirement for vesting, creating potential risk if the CFO leaves the company before the milestones are achieved.
• Failure to achieve the performance criteria will result in the forfeiture of the PSUs and options.

Future Outlook

The future outlook is dependent on the successful development, regulatory approval, and commercialization of KPL-387.

Industry Context

The development of KPL-387 for recurrent pericarditis addresses an unmet medical need in the cardiovascular space. Successful commercialization could position Kiniksa as a key player in this therapeutic area.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice in the pharmaceutical industry to align executive incentives with company performance and shareholder value.
• Companies like Amgen, Regeneron, and Vertex Pharmaceuticals also utilize similar performance-based equity awards tied to clinical trial milestones, regulatory approvals, and commercial success.
• The specific vesting criteria and earnout percentages are tailored to Kiniksa's specific development programs and strategic goals.

Stakeholder Impact

• Shareholders: Successful development and commercialization of KPL-387 could increase shareholder value.
• Employees: Achievement of milestones could lead to increased job security and potential for bonuses.
• Patients: Successful development of KPL-387 could provide a new treatment option for recurrent pericarditis.

Next Steps

• Kiniksa will need to achieve the performance criteria related to KPL-387, including submitting a BLA to the FDA and obtaining FDA approval.
• The CFO must remain employed with the company for the PSUs and options to vest, subject to certain exceptions.

Key Dates

Keywords

Kiniksa Pharmaceuticals, KNSA, Mark Ragosa, CFO, Performance Share Units, Performance Share Options, KPL-387, Recurrent Pericarditis, FDA, Biologics License Application, Vesting, Equity Compensation